Matt Calistri | Vice President, Investor Relations |
Michel Vounatsos | Chief Executive Officer |
Michael Ehlers | EVP, Research & Development |
Jeff Capello | Chief Financial Officer |
Al Sandrock | Chief Medical Officer |
Umer Raffat | Evercore |
Cory Kasimov | JP Morgan |
Ying Huang | Bank of America Merrill Lynch |
Matthew Harrison | Morgan Stanley |
Geoffrey Porges | Leerink Partners |
Michael Yee | Jefferies |
Geoff Meacham | Barclays |
Terence Finn | Goldman Sachs |
Salim Syed | Mizuho |
Robyn Karnauskas | Citi |
Phil Nadeau | Cowen & Company |
Carter Gould | UBS |
Brian Abrahams | RBC Capital Markets |
Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen's Second Quarter 2018 Financial Results and Business Update Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.